Preconditioning as a Potential Strategy for the Prevention of Parkinson’s Disease

Molecular Neurobiology

Volumn 51, Issue 1, 2015, Pages 313-330

  Golpich, Mojtaba ^a   Rahmani, Behrouz ^b   Mohamed Ibrahim, Norlinah ^a   Dargahi, Leila ^b   Mohamed, Zahurin ^c   Raymond, Azman Ali ^a   Ahmadiani, Abolhassan ^b,c  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Mitochondrial dysfunction; Oxidative stress; Parkinson s disease; Preconditioning

Indexed keywords

ADAPTATION; ANIMAL; BIOLOGICAL MODEL; HUMAN; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84897230971     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8689-6     Document Type: Review

References (160)

1. Tomiyama H, Mizuta I, Li Y, Funayama M, Yoshino H, Li L, Murata M, Yamamoto M, Kubo SI, Mizuno Y, Toda T, Hattori N (2008) LRRK2 P755L variant in sporadic Parkinson’s disease. J Hum Genet 53(11–12):1012–1015. doi:10.1007/s10038-008-0336-5
2. Tomas-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A, Venero JL (2004) Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood–brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis 16(1):190–201. doi:10.1016/j.nbd.2004.01.010
3. Korecka JA, Eggers R, Swaab DF, Bossers K, Verhaagen J (2013) Modeling early Parkinson’s disease pathology with chronic low dose MPTP treatment. Restor Neurol Neurosci 31(2):155–167
4. Greenamyre JT, Hastings TG (2004) Parkinson’s: divergent causes, convergent mechanisms. Science 304(5674):1120–1122
5. Ortega-Arellano HF, Jimenez-Del-Rio M, Velez-Pardo C (2011) Life span and locomotor activity modification by glucose and polyphenols in Drosophila melanogaster chronically exposed to oxidative stress-stimuli: implications in Parkinson’s disease. Neurochem Res 36(6):1073–1086
6. Obrenovitch TP (2008) Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev 88(1):211–247
7. Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, Iuvone PM, Weinshenker D, Greene JG, Miller GW (2009) Nonmotor symptoms of Parkinson’s disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 29(25):8103–8113
8. Gálvez-Jiménez N, Lang AE (2004) The perioperative management of Parkinson’s disease revisited. Neurol Clin 22(2):367–377
9. Pandya M, Kubu CS, Giroux ML (2008) Parkinson disease: not just a movement disorder. Cleve Clin J Med 75(12):856–864
10. Poewe W (2008) Non‐motor symptoms in Parkinson’s disease. Eur J Neurol 15(s1):14–20
11. Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376
12. Locke CJ, Fox SA, Caldwell GA, Caldwell KA (2008) Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson’s disease. Neurosci Lett 439(2):129–133. doi:10.1016/j.neulet.2008.05.003
13. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3(12):1301–1306
14. Gröger A, Bender B, Wurster I, Chadzynski GL, Klose U, Berg D (2013) Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging. J Neurol Neurosurg Psychiatry 84(6):644–649
15. Francis PT, Perry EK (2007) Cholinergic and other neurotransmitter mechanisms in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies. Mov Disord 22(S17):S351–S357
16. Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60(3):337
17. Wang S, Yan J-Y, Lo Y-K, Carvey PM, Ling Z (2009) Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide. Brain Res 1265:196–204
18. Braak H, Tredici KD, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211
19. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F (2010) Oxidative stress and aminopeptidases in Parkinson’s disease patients with and without treatment. Neurodegener Dis 8(3):109–116
20. Collins LM, Toulouse A, Connor TJ, Nolan YM (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 62(7):2154–2168. doi:10.1016/j.neuropharm.2012.01.028
21. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, Zanella F, Hilker R (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson’s disease. Brain 132(12):3285–3297
22. Anne Stetler R, Leak RK, Yin W, Zhang L, Wang S, Gao Y, Chen J (2012) Mitochondrial biogenesis contributes to ischemic neuroprotection afforded by LPS preconditioning. J Neurochem 123(s2):125–137
23. Weise J, Engelhorn T, Dörfler A, Aker S, Bähr M, Hufnagel A (2005) Expression time course and spatial distribution of activated caspase-3 after experimental status epilepticus: contribution of delayed neuronal cell death to seizure-induced neuronal injury. Neurobiol Dis 18(3):582–590
24. Folbergrová J, Ješina P, Haugvicová R, Lisý V, Houštěk J (2010) Sustained deficiency of mitochondrial complex I activity during long periods of survival after seizures induced in immature rats by homocysteic acid. Neurochem Int 56(3):394–403
25. Krieger C, Duchen MR (2002) Mitochondria, Ca(2+) and neurodegenerative disease. Eur J Pharmacol 447(2–3):177–188. doi:10.1016/s0014-2999(02)01842-3
26. +-induced cellular model of Parkinson’s disease. Neurosci Lett 475(2):89–94
27. Chuang Y-C, Lin T-K, Huang H-Y, Chang W-N, Liou C-W, Chen S-D, Chang AY, Chan SH (2012) Peroxisome proliferator-activated receptors γ/mitochondrial uncoupling protein 2 signaling protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus. J Neuroinflammation 9(1):1–18
28. Folbergrová J, Ješina P, Drahota Z, Lisý V, Haugvicová R, Vojtíšková A, Houštěk J (2007) Mitochondrial complex I inhibition in cerebral cortex of immature rats following homocysteic acid-induced seizures. Exp Neurol 204(2):597–609
29. Malinska D, Kulawiak B, Kudin AP, Kovacs R, Huchzermeyer C, Kann O, Szewczyk A, Kunz WS (2010) Complex III-dependent superoxide production of brain mitochondria contributes to seizure-related ROS formation. Biochim Biophys Acta Bioenerg 1797(6):1163–1170
30. Schapira AHV (2001) Causes of neuronal death in Parkinson’s disease. In: Calne D, Calne SM (eds) Parkinson’s disease, vol 86, Advances in neurology. Lippincott Williams & Wilkins, Philadelphia, pp 155–162
31. Zhang H, Jia H, Liu J, Ao N, Yan B, Shen W, Wang X, Li X, Luo C, Liu J (2010) Combined R‐α–lipoic acid and acetyl‐L‐carnitine exerts efficient preventative effects in a cellular model of Parkinson’s disease. J Cell Mol Med 14(1–2):215–225
32. Marongiu R, Spencer B, Crews L, Adame A, Patrick C, Trejo M, Dallapiccola B, Valente EM, Masliah E (2009) Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson’s disease by disturbing calcium flux. J Neurochem 108(6):1561–1574
33. Thomas RR, Keeney PM, Bennett JP (2012) Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex. J Parkinsons Dis 2(1):67–76
34. Ng C-H, Guan MS, Koh C, Ouyang X, Yu F, Tan E-K, O’Neill SP, Zhang X, Chung J, Lim K-L (2012) AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson’s disease. J Neurosci 32(41):14311–14317
35. Choi HJ, Lee SY, Cho Y, No H, Kim SW, Hwang O (2006) Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: implications for Parkinson’s disease. Neurochem Int 48(4):255–262
36. Becerra A, Echeverría C, Varela D, Sarmiento D, Armisén R, Nuñez-Villena F, Montecinos M, Simon F (2011) Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharide-induced endothelial cell death. Cardiovasc Res 91(4):677–684
37. Khan MM, Raza SS, Javed H, Ahmad A, Khan A, Islam F, Safhi MM, Islam F (2012) Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson’s disease. Neurotox res 22(1):1–15
38. Xue Y, Xie N, Cao L, Zhao X, Jiang H, Chi Z (2011) Diazoxide preconditioning against seizure-induced oxidative injury is via the PI3K/Akt pathway in epileptic rat. Neurosci Lett 495(2):130–134
39. Verma R, Nehru B (2009) Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson’s disease. Neurochem Int 55(6):369–375
40. Lotharius J, O’Malley KL (2000) The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation—a novel mechanism of toxicity. J Biol Chem 275(49):38581–38588. doi:10.1074/jbc.M005385200
41. Bauereis B, Haskins WE, LeBaron RG, Renthal R (2011) Proteomic insights into the protective mechanisms of an in vitro oxidative stress model of early stage Parkinson’s disease. Neurosci Lett 488(1):11–16
42. Mythri RB, Venkateshappa C, Harish G, Mahadevan A, Muthane UB, Yasha T, Bharath MS, Shankar S (2011) Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson’s disease brains. Neurochem Res 36(8):1452–1463
43. Yu J, Lyubchenko YL (2009) Early stages for Parkinson’s development: α-Synuclein misfolding and aggregation. J Neuroimmune Pharmacol 4(1):10–16
44. Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ (2010) Non‐classical exocytosis of α‐synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem 113(5):1263–1274
45. Song W, Patel A, Qureshi HY, Han D, Schipper HM, Paudel HK (2009) The Parkinson disease‐associated A30P mutation stabilizes α‐synuclein against proteasomal degradation triggered by heme oxygenase‐1 over‐expression in human neuroblastoma cells. J Neurochem 110(2):719–733
46. Stone DK, Kiyota T, Mosley RL, Gendelman HE (2012) A model of nitric oxide induced alpha-synuclein misfolding in Parkinson’s disease. Neurosci Lett 523(2):167–173. doi:10.1016/j.neulet.2012.06.070
47. Gu Z, Nakamura T, Lipton SA (2010) Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Mol Neurobiol 41(2–3):55–72
48. Chin MH, Qian W-J, Wang H, Petyuk VA, Bloom JS, Sforza DM, Laćan G, Liu D, Khan AH, Cantor RM (2008) Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson’s disease. J Proteome Res 7(2):666–677
49. Zou T, Xiao B, Tang J, Zhang H, Tang X (2012) Downregulation of Pael-R expression in a Parkinson’s disease cell model reduces apoptosis. Journal of Clinical Neuroscience
50. Meredith G, Totterdell S, Beales M, Meshul C (2009) Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson’s disease. Exp Neurol 219(1):334–340
51. Ho CC-Y, Rideout HJ, Ribe E, Troy CM, Dauer WT (2009) The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 29(4):1011–1016
52. +)-induced apoptosis in MES23. 5 cells. Neurobiol Aging 30(9):1466–1476
53. +-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol 29(8):1169–1180
54. Kaur H, Chauhan S, Sandhir R (2011) Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson’s disease. Neurochem Res 36(8):1435–1443
55. Burguillos M, Hajji N, Englund E, Persson A, Cenci A, Machado A, Cano J, Joseph B, Venero J (2011) Apoptosis-inducing factor mediates dopaminergic cell death in response to LPS-induced inflammatory stimulus: evidence in Parkinson’s disease patients. Neurobiol Dis 41(1):177–188
56. Anandhan A, Essa MM, Manivasagam T (2013) Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson’s disease. Neurotox res 23(2):166–173
57. Kiffin R, Christian C, Knecht E, Cuervo AM (2004) Activation of chaperone-mediated autophagy during oxidative stress. Mol Biol Cell 15(11):4829–4840. doi:10.1091/mbc.E04-06-0477
58. Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348(14):1356–1364
59. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP (2001) Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13(2):187–196
60. Leak RK, Liou AK, Zigmond MJ (2006) Effect of sublethal 6-hydroxydopamine on the response to subsequent oxidative stress in dopaminergic cells: evidence for preconditioning. J Neurochem 99(4):1151–1163
61. Schapira AHV, Olanow CW (2004) Neuroprotection in Parkinson disease—mysteries, myths, and misconceptions. Jama-J Am Med Assoc 291(3):358–364. doi:10.1001/jama.291.3.358
62. Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D (2009) Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson’s disease. J Mol Neurosci 39(1–2):199–210. doi:10.1007/s12031-008-9166-3
63. Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, Park JY, Bishop C (2008) Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology 199(1):99–108
64. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 123(11):2297–2305
65. Beric A, Kelly PJ, Rezai A, Sterio D, Mogilner A, Zonenshayn M, Kopell B (2002) Complications of deep brain stimulation surgery. Stereotact Funct Neurosurg 77(1–4):73–78
66. Umemura A, Jaggi JL, Hurtig HI, Siderowf AD, Colcher A, Stern MB, Baltuch GH (2003) Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. J Neurosurg 98(4):779–784. doi:10.3171/jns.2003.98.4.0779
67. Tan X, Zhang L, Qin J, Tian M, Zhu H, Dong C, Zhao H, Jin G (2012) Transplantation of neural stem cells co-transfected with Nurr1 and Brn4 for treatment of Parkinsonian rats. International Journal of Developmental Neuroscience
68. Olanow CW, Kordower JH, Lang AE, Obeso JA (2009) Dopaminergic transplantation for Parkinson’s disease: current status and future prospects. Ann Neurol 66(5):591–596. doi:10.1002/ana.21778
69. O’Keeffe FE, Scott SA, Tyers P, O’Keeffe GW, Dalley JW, Zufferey R, Caldwell MA (2008) Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson’s disease. Brain 131(3):630–641
70. Huang RQ, Ke WL, Liu Y, Wu DD, Feng LY, Jiang C, Pei YY (2010) Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci 290(1–2):123–130. doi:10.1016/j.jns.2009.09.032
71. Wettergren EE, Gussing F, Quintino L, Lundberg C (2012) Novel disease-specific promoters for use in gene therapy for Parkinson’s disease. Neuroscience letters
72. Feng LR, Maguire-Zeiss KA (2010) Gene therapy in Parkinson’s disease rationale and current status. Cns Drugs 24(3):177–192
73. Antony S, DebRoy P, Vadivelan R, Jaysankar K, Vikram M, Nandini S, Sundeep M, Elango K, Suresh B (2010) Amelioration of CNS toxicities of L-dopa in experimental models of Parkinson’s disease by concurrent treatment with Tinospora cordifolia. Hygeia J D Med 2(1):28–37
74. Kim JH, Lee HW, Hwang J, Kim J, Lee MJ, Han HS, Lee WH, Suk K (2012) Microglia-inhibiting activity of Parkinson’s disease drug amantadine. Neurobiol Aging 33(9):2145–2159. doi:10.1016/j.neurobiolaging.2011.08.011
75. Yuan H, Zhang ZW, Liang LW, Shen Q, Wang XD, Ren SM, Ma HJ, Jiao SJ, Liu P (2010) Treatment strategies for Parkinson’s disease. Neurosci Bull 26(1):66–76. doi:10.1007/s12264-010-0302-z
76. Tribl GG, Wober C, Schonborn V, Brucke T, Deecke L, Panzer S (2001) Amantadine in Parkinson’s disease: lymphocyte subsets and IL-2 secreting T cell precursor frequencies. Exp Gerontol 36(10):1761–1771. doi:10.1016/s0531-5565(01)00128-0
77. Navailles S, Bioulac B, Gross C, De Deurwaerdère P (2011) Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson’s disease. Neurobiol Dis 41(2):585–590
78. Poewe W (2006) The need for neuroprotective therapies in Parkinson’s disease A clinical perspective. Neurology 66(10 suppl 4):S2–S9
79. Reimers D, Herranz AS, Diaz-Gil JJ, Lobo MVT, Paíno CL, Alonso R, Asensio MJ, Gonzalo-Gobernado R, Bazán E (2006) Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats. J Histochem Cytochem 54(4):457–465
80. Colafrancesco V, Villoslada P (2011) Targeting NGF-pathway for developing neuroprotective therapies for multiple sclerosis and other neurological diseases. Arch Ital Biol 149(2):183–192
81. Jin F, Wu Q, Lu Y-F, Gong Q-H, Shi J-S (2008) Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson’s disease in rats. Eur J Pharmacol 600(1):78–82
82. Casper D, Yaparpalvi U, Rempel N, Werner P (2000) Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 289(3):201–204
83. Krauss JK, Jankovic J (1996) Surgical treatment of Parkinson’s disease. Am Fam Physician 54(5):1621–1629
84. Olanow CW (2008) Levodopa/dopamine replacement strategies in Parkinson’s disease—Future directions. Mov Disord 23:S613–S622. doi:10.1002/mds.22061
85. Singh N, Pillay V, Choonara YE (2007) Advances in the treatment of Parkinson’s disease. Prog Neurobiol 81(1):29–44
86. Betchen SA, Kaplitt M (2003) Future and current surgical therapies in Parkinson’s disease. Curr Opin Neurol 16(4):487–493
87. Thevathasan W, Coyne TJ, Hyam JA, Kerr G, Jenkinson N, Aziz TZ, Silburn PA (2011) Pedunculopontine nucleus stimulation improves gait freezing in Parkinson disease. Neurosurgery 69(6):1248–1254
88. Chao Y, Gang L, Na Z, Ming W, Zhong W, Mian W (2007) Surgical management of parkinson’s disease: update and review. Interv Neuroradiol 13(4):359
89. Kelly PJ, Ahlskog J, Goerss SJ, Daube JR, Duffy JR, Kall BA Computer-assisted stereotactic ventralis lateralis thalamotomy with microelectrode recording control in patients with Parkinson’s disease. In: Mayo Clinic Proceedings, 1987. vol 8. Elsevier, pp 655–664
90. Matsumoto K, Asano T, Baba T, Miyamoto T, Ohmoto T (1976) Long-term follow-up results of bilateral thalamotomy for parkinsonism. Stereotact Funct Neurosurg 39(3–4):257–260
91. Hamani C, Neimat J (2006) Deep brain stimulation for the treatment of Parkinson’s disease. Parkinson’s Disease and Related Disorders. Springer, In, pp 393–399
92. Drucker-Colín R, Verdugo-Díaz L (2004) Cell transplantation for Parkinson’s disease: present status. Cell Mol Neurobiol 24(3):301–316
93. Lindvall O, Björklund A (2004) Cell therapy in Parkinson’s disease. NeuroRx 1(4):382–393
94. Cova L, Armentero M-T, Zennaro E, Calzarossa C, Bossolasco P, Lambertenghi Deliliers G, Polli E, Nappi G, Silani V, Blandini F (2010) Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson’s disease. Brain research 1311:12–27
95. Okano H, Sakaguchi M, Ohki K, Suzuki N, Sawamoto K (2007) Regeneration of the central nervous system using endogenous repair mechanisms. J Neurochem 102(5):1459–1465
96. Ren Z, Wang J, Wang S, Zou C, Li X, Guan Y, Chen Z, Zhang YA (2013) Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys. Sci rep 3
97. Ziavra D, Makri G, Giompres P, Taraviras S, Thomaidou D, Matsas R, Mitsacos A, Kouvelas ED (2012) Neural stem cells transplanted in a mouse model of Parkinson’s disease differentiate to neuronal phenotypes and reduce rotational deficit. CNS Neurol Disord Drug Targets 11(7):829–835
98. Bouchez G, Sensebé L, Vourc’h P, Garreau L, Bodard S, Rico A, Guilloteau D, Charbord P, Besnard J-C, Chalon S (2008) Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson’s disease. Neurochem Int 52(7):1332–1342
99. Campeau L, Soler R, Sittadjody S, Pareta R, Nomiya M, Zarifpour M, Opara EC, Yoo JJ, Andersson KE (2013) Effects of allogeneic bone marrow-derived mesenchymal stromal cell therapy on voiding function in a rat model of Parkinson’s disease. The Journal of urology
100. Yasuhara T, Date I (2009) Gene therapy for Parkinson’s disease. Birth, Life and Death of Dopaminergic Neurons in the Substantia Nigra. Springer, In, pp 301–309
101. Douglas MR (2013) Gene therapy for Parkinson’s disease: state-of-the-art treatments for neurodegenerative disease. Expert Rev Neurother 13(6):695–705
102. Jerusalinsky D, Baez MV, Epstein AL (2012) Herpes simplex virus type 1-based amplicon vectors for fundamental research in neurosciences and gene therapy of neurological diseases. J Physiol Paris 106(1–2):2–11. doi:10.1016/j.jphysparis.2011.11.003
103. Leriche L, Bjorklund T, Breysse N, Besret L, Gregoire MC, Carlsson T, Dolle F, Mandel RJ, Deglon N, Hantraye P, Kirik D (2009) Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. J Neurosci 29(5):1544–1553. doi:10.1523/jneurosci.4491-08.2009
104. Ren X, Zhang T, Gong X, Hu G, Ding W, Wang X (2013) AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Experimental neurology
105. Cederfjäll E, Nilsson N, Sahin G, Chu Y, Nikitidou E, Björklund T, Kordower JH, Kirik D (2013) Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson’s disease. Sci rep 3
106. Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-Daifoti Z, Kirik D, Stefanis L (2013) Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. Brain
107. Steiner B, Witte V, Floel A (2011) Lifestyle and cognition. What do we know from the aging and neurodegenerative brain? Nervenarzt 82(12):1566–1577. doi:10.1007/s00115-011-3353-0
108. Baroni L, Bonetto C, Tessan F, Goldin D, Cenci L, Magnanini P, Zuliani G (2011) Pilot dietary study with normoproteic protein-redistributed plant-food diet and motor performance in patients with Parkinson’s disease. Nutr Neurosci 14(1):1–9. doi:10.1179/174313211x12966635733231
109. Cheng BH, Yang XX, An LX, Gao B, Liu X, Liu SW (2009) Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson’s disease. Brain Res 1286:25–31. doi:10.1016/j.brainres.2009.06.060
110. Tajiri N, Yasuhara T, Shingo T, Kondo A, Yuan W, Kadota T, Wang F, Baba T, Tayra JT, Morimoto T (2010) Exercise exerts neuroprotective effects on Parkinson’s disease model of rats. Brain Res 1310:200–207
111. Döbrössy MD, Dunnett SB (2003) Motor training effects on recovery of function after striatal lesions and striatal grafts. Exp Neurol 184(1):274–284
112. Faherty CJ, Raviie Shepherd K, Herasimtschuk A, Smeyne RJ (2005) Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Mol Brain Res 134(1):170–179
113. Wu SY, Wang TF, Yu L, Jen CJ, Chuang JI, Wu FS, Wu CW, Kuo YM (2011) Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway. Brain Behav Immun 25(1):135–146. doi:10.1016/j.bbi.2010.09.006
114. Cotman CW, Berchtold NC (2002) Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 25(6):295–301
115. Carro E, Nuñez A, Busiguina S, Torres-Aleman I (2000) Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci 20(8):2926–2933
116. 9 −tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage. Behav Brain Res 220(1):194–201
117. Vandresen-Filho S, de Araújo HB, Franco JL, Boeck CR, Dafre AL, Tasca CI (2007) Evaluation of glutathione metabolism in NMDA preconditioning against quinolinic acid-induced seizures in mice cerebral cortex and hippocampus. Brain Res 1184:38–45
118. de Araújo HB, Vandresen-Filho S, Martins WC, Boeck CR, Tasca CI (2011) NMDA preconditioning protects against quinolinic acid-induced seizures via PKA, PI3K and MAPK/ERK signaling pathways. Behav Brain Res 219(1):92–97
119. Dmowska M, Cybulska R, Schoenborn R, Piersiak T, Jaworska-Adamu J, Gawron A (2010) Behavioural and histological effects of preconditioning with lipopolysaccharide in epileptic rats. Neurochem Res 35(2):262–272
120. Hickey E, Shi H, Van Arsdell G, Askalan R (2011) Lipopolysaccharide-induced preconditioning against ischemic injury is associated with changes in Toll-like receptor 4 expression in the rat developing brain. Pediatr Res 70(1):10–14
121. Jimenez-Mateos EM, Hatazaki S, Johnson MB, Bellver-Estelles C, Mouri G, Bonner C, Prehn JH, Meller R, Simon RP, Henshall DC (2008) Hippocampal transcriptome after status epilepticus in mice rendered seizure damage-tolerant by epileptic preconditioning features suppressed calcium and neuronal excitability pathways. Neurobiol Dis 32(3):442–453
122. Chen Z, Jalabi W, Shpargel KB, Farabaugh KT, Dutta R, Yin X, Kidd GJ, Bergmann CC, Stohlman SA, Trapp BD (2012) Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4. J Neurosci 32(34):11706–11715
123. Tzeng YW, Lee LY, Chao PL, Lee HC, Wu RT, Lin AMY (2010) Role of autophagy in protection afforded by hypoxic preconditioning against MPP + −induced neurotoxicity in SH-SY5Y cells. Free Radic Biol Med 49(5):839–846. doi:10.1016/j.freeradbiomed.2010.06.004
124. Orio M, Kunz A, Kawano T, Anrather J, Zhou P, Iadecola C (2007) Lipopolysaccharide induces early tolerance to excitotoxicity via nitric oxide and cGMP. Stroke 38(10):2812–2817. doi:10.1161/strokeaha.107.486837
125. Racay P, Chomova M, Tatarkova Z, Kaplan P, Hatok J, Dobrota D (2009) Ischemia-induced mitochondrial apoptosis is significantly attenuated by ischemic preconditioning. Cell Mol Neurobiol 29(6–7):901–908
126. Stenzel-Poore MP, Stevens SL, King JS, Simon RP (2007) Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes a speculative synthesis. Stroke 38(2):680–685
127. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP (2009) Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 158(3):1007–1020. doi:10.1016/j.neuroscience.2008.07.067
128. Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP, Stenzel-Poore MP (2011) Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci 31(23):8456–8463. doi:10.1523/jneurosci.0821-11.2011
129. Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, Harrington CA, Stenzel-Poore MP (2009) Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J Neurosci 29(31):9839–9849
130. Vartanian KB, Stevens SL, Marsh BJ, Williams-Karnesky R, Lessov NS, Stenzel-Poore MP (2011) LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury. J Neuroinflammation 8(1):140
131. Rosenzweig HL, Minami M, Lessov NS, Coste SC, Stevens SL, Henshall DC, Meller R, Simon RP, Stenzel-Poore MP (2007) Endotoxin preconditioning protects against the cytotoxic effects of TNFα after stroke: a novel role for TNFα in LPS-ischemic tolerance. J Cereb Blood Flow Metab 27(10):1663–1674
132. Arnold B, Cassady SJ, VanLaar VS, Berman SB (2011) Integrating multiple aspects of mitochondrial dynamics in neurons: age-related differences and dynamic changes in a chronic rotenone model. Neurobiol Dis 41(1):189–200
133. Sheng B, Wang X, Su B, Hg L, Casadesus G, Perry G, Zhu X (2012) Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem 120(3):419–429
134. Valerio A, Bertolotti P, Delbarba A, Perego C, Dossena M, Ragni M, Spano P, Carruba MO, De Simoni MG, Nisoli E (2011) Glycogen synthase kinase‐3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. J Neurochem 116(6):1148–1159
135. Cronin-Furman EN, Borland MK, Bergquist KE, Bennett JP Jr, Trimmer PA (2013) Mitochondrial quality, dynamics and functional capacity in Parkinson’s disease cybrid cell lines selected for Lewy body expression. Mol Neurodegener 8(1):6
136. Keeney PM, Dunham LD, Quigley CK, Morton SL, Bergquist KE, Bennett JP (2009) Cybrid models of Parkinson’s disease show variable mitochondrial biogenesis and genotype-respiration relationships. Exp Neurol 220(2):374–382
137. Gutsaeva DR, Carraway MS, Suliman HB, Demchenko IT, Shitara H, Yonekawa H, Piantadosi CA (2008) Transient hypoxia stimulates mitochondrial biogenesis in brain subcortex by a neuronal nitric oxide synthase dependent mechanism. J Neurosci 28(9):2015–2024. doi:10.1523/jneurosci.5654-07.2008
138. Zhang Q, Wu Y, Zhang P, Sha H, Jia J, Hu Y, Zhu J (2012) Exercise induces mitochondrial biogenesis after brain ischemia in rats. Neuroscience 205:10–17
139. Han Y, Lin Y, Xie N, Xue Y, Tao H, Rui C, Xu J, Cao L, Liu X, Jiang H (2011) Impaired mitochondrial biogenesis in hippocampi of rats with chronic seizures. Neuroscience 194:234–240
140. Vernochet C, Mourier A, Bezy O, Macotela Y, Boucher J, Rardin MJ, An D, Lee KY, Ilkayeva OR, Zingaretti CM (2012) Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice against obesity and insulin resistance. Cell metabolism
141. Yin W, Signore AP, Iwai M, Cao GD, Gao YQ, Chen J (2008) Rapidly increased neuronal mitochondrial biogenesis after hypoxic-ischemic brain injury. Stroke 39(11):3057–3063. doi:10.1161/strokeaha.108.520114
142. Raval AP, Dave KR, Perez-Pinzon MA (2006) Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab 26(9):1141–1147. doi:10.1038/sj.jcbfm.9600262
143. Ding Y, Li L (2008) Lipopolysaccharide preconditioning induces protection against lipopolysaccharide-induced neurotoxicity in organotypic midbrain slice culture. Neurosci bull 24(4):209–218
144. Eklind S, Mallard C, Arvidsson P, Hagberg H (2005) Lipopolysaccharide induces both a primary and a secondary phase of sensitization in the developing rat brain. Pediatr Res 58(1):112–116
145. Fan HK, Cook JA (2004) Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 10(2):71–84. doi:10.1179/096805104225003997
146. Longhi L, Gesuete R, Perego C, Ortolano F, Sacchi N, Villa P, Stocchetti N, De Simoni M-G (2011) Long-lasting protection in brain trauma by endotoxin preconditioning. J Cereb Blood Flow Metab 31(9):1919–1929
147. Longhi L, Perego C, Sacchi N, Zanier E, Ortolano F, Stocchetti N, McIntosh T, De Simoni MG (2009) LPS preconditioning attenuates neurobehavioral deficits following controlled cortical impact brain injury in mice. J Cereb Blood Flow Metab 29:S198–S199
148. Kumral A, Tuzun F, Ozbal S, Ergur BU, Yilmaz O, Duman N, Ozkan H (2012) Lipopolysaccharide-preconditioning protects against endotoxin-induced white matter injury in the neonatal rat brain. Brain Res 1489:81–89. doi:10.1016/j.brainres.2012.10.015
149. Yu JT, Lee CH, Yoo KY, Choi JH, Li H, Park OK, Yan B, Hwang IK, Kwon YG, Kim YM, Won MH (2010) Maintenance of anti-inflammatory cytokines and reduction of glial activation in the ischemic hippocampal CA1 region preconditioned with lipopolysaccharide. J Neurol Sci 296(1–2):69–78. doi:10.1016/j.jns.2010.06.004
150. Hiasa G, Hamada M, Ikeda S, Hiwada K (2001) Ischemic preconditioning and lipopolysaccharide attenuate nuclear factor-kappa B activation and gene expression of inflammatory cytokines in the ischemia-reperfused rat heart. Jpn Circ J-English Edition 65(11):984–990. doi:10.1253/jcj.65.984
151. Lin HY, Wu CL, Huang CC (2010) The Akt-endothelial nitric oxide synthase pathway in lipopolysaccharide preconditioning-induced hypoxic-ischemic tolerance in the neonatal rat brain. Stroke 41(7):1543–1551. doi:10.1161/strokeaha.109.574004
152. Mirrione MM, Konomos DK, Gravanis I, Dewey SL, Aguzzi A, Heppner FL, Tsirka SE (2010) Microglial ablation and lipopolysaccharide preconditioning affects pilocarpine-induced seizures in mice. Neurobiol Dis 39(1):85–97
153. Choi D-Y, Liu M, Hunter RL, Cass WA, Pandya JD, Sullivan PG, Shin E-J, Kim H-C, Gash DM, Bing G (2009) Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 4(5):e5482
154. Hara H, Kamiya T, Adachi T (2011) Endoplasmic reticulum stress inducers provide protection against 6-hydroxydopamine-induced cytotoxicity. Neurochem Int 58(1):35–43
155. Rodriguez-Pallares J, Parga JA, Munoz A, Rey P, Guerra AJ, Labandeira-Garcia JL (2007) Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem 103(1):145–156. doi:10.1111/j.1471-4159.2007.04699.x
156. Chen ZH, Yoshida Y, Saito Y, Niki E (2005) Adaptation to hydrogen peroxide enhances PC12 cell tolerance against oxidative damage. Neurosci Lett 383(3):256–259. doi:10.1016/j.neulet.2005.04.022
157. Hamidi GA, Faraji A, Zarmehri HA, Haghdoost-Yazdi H (2012) Prolonged hyperoxia preconditioning attenuates behavioral symptoms of 6-hydroxydopamine-induced Parkinsonism. Neurol Res 34(7):636–642. doi:10.1179/1743132812y.0000000056
158. Cannon JR, Keep RF, Hua Y, Richardson RJ, Schallert T, Xi GH (2005) Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson’s disease model. Neurosci Lett 373(3):189–194. doi:10.1016/j.neulet.2004.10.089
159. Vajda FJ (2002) Neuroprotection and neurodegenerative disease. J Clin Neurosci 9(1):4–8
160. Seidl SE, Potashkin JA (2011) The promise of neuroprotective agents in Parkinson’s disease. Front Neurol 2